These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11229774)

  • 1. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).
    Fray MJ; Dickinson RP
    Bioorg Med Chem Lett; 2001 Feb; 11(4):571-4. PubMed ID: 11229774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
    Fray MJ; Burslem MF; Dickinson RP
    Bioorg Med Chem Lett; 2001 Feb; 11(4):567-70. PubMed ID: 11229773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel series of highly selective inhibitors of MMP-3.
    Whitlock GA; Dack KN; Dickinson RP; Lewis ML
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
    Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
    Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.
    Marcq V; Mirand C; Decarme M; Emonard H; Hornebeck W
    Bioorg Med Chem Lett; 2003 Sep; 13(17):2843-6. PubMed ID: 14611841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
    Sheppard GS; Florjancic AS; Giesler JR; Xu L; Guo Y; Davidsen SK; Marcotte PA; Elmore I; Albert DH; Magoc TJ; Bouska JJ; Goodfellow CL; Morgan DW; Summers JB
    Bioorg Med Chem Lett; 1998 Nov; 8(22):3251-6. PubMed ID: 9873712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II.
    Stoermer D; Liu Q; Hall MR; Flanary JM; Thomas AG; Rojas C; Slusher BS; Tsukamoto T
    Bioorg Med Chem Lett; 2003 Jul; 13(13):2097-100. PubMed ID: 12798312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
    Levin JI; Gu Y; Nelson FC; Zask A; DiJoseph JF; Sharr MA; Sung A; Jin G; Cowling R; Chanda P; Cosmi S; Hsiao CL; Edris W; Wilhelm J; Killar LM; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Jan; 11(2):239-42. PubMed ID: 11206468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quantitative structure-activity relationship study on some novel series of hydroxamic acid analogs acting as matrix metalloproteinase inhibitors.
    Kumaran S; Gupta SP
    Med Chem; 2007 Mar; 3(2):167-73. PubMed ID: 17348854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinyl hydroxamate and iminodiacetic acid hydroxamate moieties.
    Santos MA; Marques S; Gil M; Tegoni M; Scozzafava A; Supuran CT
    J Enzyme Inhib Med Chem; 2003 Jun; 18(3):233-42. PubMed ID: 14506914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.
    Levin JI; Du MT; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Moy FJ; Powers R; Jin G; Cowling R; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Jan; 11(2):235-8. PubMed ID: 11206467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
    Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
    Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.
    Hajduk PJ; Shuker SB; Nettesheim DG; Craig R; Augeri DJ; Betebenner D; Albert DH; Guo Y; Meadows RP; Xu L; Michaelides M; Davidsen SK; Fesik SW
    J Med Chem; 2002 Dec; 45(26):5628-39. PubMed ID: 12477346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxamate derivatives of substrate-analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases.
    Krumme D; Wenzel H; Tschesche H
    FEBS Lett; 1998 Oct; 436(2):209-12. PubMed ID: 9781680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE.
    Levin JI
    Curr Top Med Chem; 2004; 4(12):1289-310. PubMed ID: 15320727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
    Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
    Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
    Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
    Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
    J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
    Kottirsch G; Koch G; Feifel R; Neumann U
    J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.